Join the Versed group to help and get support from people like you.
Versed News
Study Looks at Links Between Anxiety Disorders, Benzodiazepines, Dementia
MONDAY, Aug. 14, 2023 – Benzodiazepines and anxiety disorders are associated with dementia risk, but for patients with anxiety disorders, no additional risk is seen with benzodiazepine use,...
Variation Seen in Dosing of Meds at Prehospital Pediatric Encounters
MONDAY, July 10, 2023 – For pediatric patients in the prehospital setting, weight-based dosing often varies from national guidelines, according to a study published online July 10 in Pediatrics....
FDA Medwatch Alert: Drug Safety Communication: Benzodiazepine Drug Class - Boxed Warning Updated to Improve Safe Use
ISSUE: The FDA is requiring the Boxed Warning, FDA’s most prominent warning, be updated by adding other information to the prescribing information for all benzodiazepine medicines. This information w...
FDA Medwatch Alert: General Anesthetic and Sedation Drugs: Drug Safety Communication - FDA Approves Label Changes for Use in Young Children
ISSUE: FDA has approved previously announced label changes regarding the use of general anesthetic and sedation medicines in children younger than 3 years. These changes include: A new Warning...
FDA Medwatch Alert: General Anesthetic and Sedation Drugs: Drug Safety Communication - New Warnings for Young Children and Pregnant Women
ISSUE: FDA is warning that repeated or lengthy use of general anesthetic and sedation drugs during surgeries or procedures in children younger than 3 years or in pregnant women during their third...
FDA Medwatch Alert: Opioid Pain or Cough Medicines Combined With Benzodiazepines: Drug Safety Communication - FDA Requiring New Boxed Warnings About Serious Risks and Death
ISSUE: FDA review has found that the growing combined use of opioid medicines with benzodiazepines or other drugs that depress the central nervous system (CNS) has resulted in serious side effects,...
FDA Medwatch Alert: Versed Syrup (midazolam HCl) CIV
Roche Laboratories is conducting a voluntary Class I drug recall of 118 mL (2mg/mL) bottle, lots U0009-50 and U0010-50, because of the potential presence of a crystalline precipitate of an insoluble...
Ask a question
To post your own question to this support group, sign in or create an account.